FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition of antibacterial action, comprising active substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazin-2-(2,4-difluorophenyl)-carboxamide in a crystalline form with a particle size of less than 50 mcm in amount of 150 to 600 mg in the form of an oral solid dosage form with acceptable excipients. Invention also relates to use of said pharmaceutical composition for treating acute, recurrent and chronic infections, such as complicated urinary tract infections, pneumonia, chronic urogenital infections, acute and chronic intestinal localization infections, caused by antibiotic-resistant strains of Pseudomonas aeruginosa, Enterococcus spp., Chlamydia trachomatis, Salmonella spp.
EFFECT: technical result is obtaining a new pharmaceutical composition which can find application in medicine.
4 cl, 32 tbl, 14 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DISPERSION of 4- (3-ETHOXY-4-HYDROXIBENZIL) -5-OXO-5,6-DIHYDRO-4H- [1,3,4] -THIADIAZINE-2- (2,4-DIFLUOROPHENYL) -CARBOXAMIDE FOR PRODUCING PHARMACEUTICAL FORMULATION AND METHOD OF TREATMENT OF CHRONIC INFECTIOUS DISEASES | 2020 |
|
RU2743927C1 |
| APPLICATION OF 4-(3-ETHOXY-4-HYDROXYBENZYL)-5-OXO-5,6-DIHYDRO-4H-[1,3,4]-THIADIAZINE-2-(2,4-DIFLUOROPHENYL)-CARBOXAMIDE TO SUPPRESS INFECTION, CAUSED BY ANTIBIOTIC-RESISTANT PSEUDOMONAS AERUGINOSA STRAINS, AND METHOD OF SUPPRESSION OF THIS INFECTION | 2016 |
|
RU2624846C1 |
| DRUG FOR TREATMENT OF BACTERIAL INFECTIONS | 2019 |
|
RU2778521C2 |
| METHOD FOR TREATMENT OF HUMAN DISEASES CAUSED BY GRAM-POSITIVE BACTERIA | 2017 |
|
RU2661613C1 |
| PHARMACEUTICAL COMPOSITION AND KIT FOR TREATING BACTERIAL INFECTIONS | 2011 |
|
RU2496475C2 |
| METHOD OF TOXOPLASMOSIS SEVERITY DECREASE, PHARMACEUTICAL COMPOSITION, USE OF RIFAMPYCIN DERIVATIVES FOR PREPARING DRUGS FOR TREATMENT OF PATIENTS WITH TOXOPLASMOSIS | 1994 |
|
RU2121838C1 |
| METHOD AND AGENT ACTIVATING IRF-3 FOR TREATING AND PREVENTING DISEASES CAUSED BY (+) RNA CONTAINING VIRUSES | 2012 |
|
RU2518314C2 |
| METHOD FOR PREPARING HIGH-BIOAVAILABILITY RIFABUTIN COMPOSITION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING MYCOBACTERIOSIS | 2013 |
|
RU2520603C1 |
| PALLADIUM-COPPER CATALYSTS FOR HOMOGENEOUS SELECTIVE OXIDATION OF THIOL GROUPS, COMBINATION AND COMPOSITION BASED ON SAID CATALYSTS AND THERAPEUTIC TREATMENT METHOD | 2011 |
|
RU2451010C1 |
| METHOD FOR PRODUCTION OF POLYMORPHOUS FORM OF 4-(3-ETHOXY-4-HYDROXYBENZYL)-N-(2,4-DIFLUORPHENYL)-5-OXO-5,6-DIHYDRO-4H-1,3,4-THIADIZINE-2-CARBOXAMIDE | 2022 |
|
RU2785195C1 |
